Nuclear and mitochondrial DNA alterations in pheochromocytomas and paragangliomas, and their potential treatment

Area of Science:

• Endocrinology
• Oncology
• Genetics

Background:

• Mitochondrial DNA (mtDNA) alterations are implicated in various cancers.
• Pheochromocytomas and paragangliomas (PCCs/PGLs) are rare endocrine tumors derived from chromaffin cells.
• The genetic basis of ~60% of PCCs/PGLs involves nuclear DNA alterations, but mitochondrial involvement is less understood.

Purpose of the Study:

• To review current knowledge on nuclear and mitochondrial DNA alterations in PCCs/PGLs.
• To explore the role of these alterations in tumor formation and metastasis.
• To provide insights into PCCs/PGLs genetics, molecular pathways, and therapeutic strategies.

Main Methods:

• Literature review of recent studies on PCCs/PGLs genetics.
• Synthesis of information on both nuclear and mitochondrial DNA alterations.
• Analysis of molecular pathways and potential therapeutic targets.

Main Results:

• Mitochondrial alterations are identified in approximately 17% of PCCs/PGLs.
• Both nuclear and mitochondrial DNA changes contribute to PCCs/PGLs development.
• Recent studies highlight the significance of mitochondrial alterations in these tumors.

Conclusions:

• Mitochondrial DNA alterations represent a significant factor in a subset of PCCs/PGLs.
• Understanding these genetic changes is crucial for identifying novel therapeutic targets.
• Further research into mtDNA's role can advance PCCs/PGLs treatment strategies.